@article {Graff-RadfordP6.332作者={乔纳森Graff-Radford和梅丽莎·默里Val劳和布拉德利Boeve坦尼斯Ferman和斯科特Przybelski和盖Lesnick和马修Senjem杰弗瑞甘特和格伦·史密斯和David Knopman Clifford杰克和丹尼斯·迪克森和罗纳德·彼得森和Kejal Kantarci}, title ={与路易体痴呆:病理基础的扣带岛标志(P6.332)},体积={82}={10}补充数量,elocation-id = {P6.332} ={2014},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={摘要目的:探讨临床、影像和病理协会的扣带岛(CIS)和路易体痴呆迹象(下文)。首页背景:临床诊断下文仍然不佳,尽管改善临床标准。抽出后扣带相对于楔片和楔前叶(CIS),已被建议作为[18 f] 2-fluoro-deoxy-D-glucose (FDG) PET生物标记来区分下文从{\ textquoteright}年代老年痴呆症(广告)的病理基础是未知的迹象。设计/方法:我们回顾性确定连续病例的临床诊断下文(n = 39)和匹配广告(n = 39)和患者认知正常受试者(n = 78)接受FDG和11 c-pittsburgh化合物b(加以)PET扫描。我们研究的病人尸检(n = 10)和接受Braak-neurofibrillary混乱(非功能性测试)阶段。结果:受试者的临床诊断下文亦有明显高于CIS FDG PET相比,广告主题\ (p < 0.001),这是独立存在的β-amyloid负载加以宠物(p = 0.66)。尸检确诊病例,6/8的患者临床诊断下文的中间或高可能性下文病理学和积极的CIS FDG PET的视觉评估。2/8与临床下文但负面CIS AD病理诊断。CIS是消极的广告在两个患者临床诊断,证实了尸检。更高的CIS与较低的Braak-NFT阶段(r = -0.92; p\<0.001). CONCLUSIONS: Our study finds that the presence of the CIS on FDG PET is not associated with β-amyloid load, but indicates a lower Braak-NFT stage in patients with DLB. Patients with a positive CIS fit into the high or intermediate probability DLB pathology group and are clinically diagnosed with DLB not AD. Identifying biomarkers which can measure relative contributions of underlying pathologies to a patient{\textquoteright}s dementia is critical as neurotherapeutics moves towards targeted treatments. Study Supported by: AG040042/AG11378/AG16574/AG06786/Mangurian FoundationDisclosure: Dr. Graff-Radford has nothing to disclose. Dr. Murray has nothing to disclose. Dr. Lowe has received personal compensation for activities with Bayer Pharmaceuticals Corp. Dr. Lowe has received research support from GE Health Care, Siemens Molecular Imaging, and AVID Radiopharmaceuticals, Inc. Dr. Boeve has received research support from Cephalon, Inc., Allon Therapeutics, and GE Healthcare. Dr. Ferman has nothing to disclose. Dr. Przybelski has nothing to disclose. Dr. Lesnick has received personal compensation for activities with Reproductive Medicine and Infertility Associates as a consultant. Dr. Senjem has nothing to disclose. Dr. Gunter has nothing to disclose. Dr. Smith has nothing to disclose. Dr. Knopman has received personal compensation for activities with Eli Lilly \& Company and TauRx Pharmaceuticals. Dr. Knopman has received personal compensation in an editorial capacity for Neurology. Dr. Knopman has received research support from Janssen and Baxter. Dr. Jack has received personal compensation for activities with Janssen, Eisai Inc., General Electric, Johnson \& Johnson, and Eli Lilly \& Co. Dr. Jack has received research support from Pfizer Inc., Allon, and Baxter. Dr. Dickson has received personal compensation for activities with Neotope, Inc. as a consultant. Dr. Petersen has received personal compensation for activities with Pfizer, Inc., and Janssen Alzheimer{\textquoteright}s Immunotherapy. Dr. Petersen has received royalty payments from Oxford University Press. Dr. Kantarci has received research support from Pfizer Inc., Jannsen Alzheimer immunotherapy, and Takeda Global Research \& Development Center.Thursday, May 1 2014, 7:30 am-11:00 am}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/82/10_Supplement/P6.332}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }